Carboplatin

Endometrial Adenocarcinoma

Daniela Matei, MDSmall moleculePhase 2Dormant

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 95/ 100

Competitive context

12 Active assets in the Endometrial Adenocarcinoma cohort.

Asset / Sponsor	Phase	Rating
Olaparib National Cancer Institute (NCI)	Phase 2	B
Capivasertib National Cancer Institute (NCI)	Phase 2	B
Cediranib National Cancer Institute (NCI)	Phase 2	B
Metformin University of Arkansas	Phase 2	B
Pembrolizumab Daniela Matei, MD	Phase 2	B

View all 22 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant

A

Indicative ·

80 / 100

non-small cell squamous lung carcinomaDormant

BBB

Indicative ·

76 / 100

primary peritoneal carcinomaDormant

BBB

Indicative ·

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.